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Background: The introduction of next generation sequencing (NGS) has revolutionized molecular diagnostics,
though several challenges remain limiting the widespread adoption of NGS testing into clinical practice. One such
difficulty includes the development of a robust bioinformatics pipeline that can handle the volume of data
generated by high-throughput sequencing in a cost-effective manner. Analysis of sequencing data typically requires
a substantial level of computing power that is often cost-prohibitive to most clinical diagnostics laboratories.
Findings: To address this challenge, our institution has developed a Galaxy-based data analysis pipeline which relies
on a web-based, cloud-computing infrastructure to process NGS data and identify genetic variants. It provides
additional flexibility, needed to control storage costs, resulting in a pipeline that is cost-effective on a per-sample
basis. It does not require the usage of EBS disk to run a sample.
Conclusions: We demonstrate the validation and feasibility of implementing this bioinformatics pipeline in a
molecular diagnostics laboratory. Four samples were analyzed in duplicate pairs and showed 100% concordance in
mutations identified. This pipeline is currently being used in the clinic and all identified pathogenic variants
confirmed using Sanger sequencing further validating the software.
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Background
Next generation sequencing (NGS) technology has re-
cently been introduced into clinical diagnostics, having
already profoundly changed the nature and scope of gen-
omic research in prior years. The large volume of data
generated at relatively low cost makes NGS an ideal plat-
form for comprehensive mutation analysis of both consti-
tutional disorders (i.e. germline alterations) and cancer
diagnostics (i.e. somatic alterations). Sequencing single
genes in the work-up of suspected inherited conditions
using traditional Sanger sequencing methods have historic-
ally been time consuming and costly. However, with the ad-
vent of NGS, clinical laboratories can offer cost-effective
comprehensive gene panels for several complex inherited* Correspondence: kats@umn.edu
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unless otherwise stated.disorders [1,2]. Likewise, the field of cancer biology has rap-
idly evolved with the identification of a finite number of on-
cogenes and tumor-suppressor genes commonly implicated
in a variety of tumors [3]. As we enter the era of personal-
ized medicine, NGS offers the opportunity to conduct com-
prehensive genetic analysis of cancers as part of routine
companion diagnostic testing to guide appropriate therapy
[4,5]. More recently, NGS testing has even entered the
realm of clinical infectious disease testing, primarily
with sequencing of the bacterial 16S rRNA gene region
[6]. Thus, NGS testing has broad clinical applicability
and is ideally suited to address diagnostic issues across
multiple medical specialties.
One major challenge to implementation of NGS based
technology in clinical laboratories is the development of
scalable and robust bioinformatics infrastructure (human
and computational resources) to effectively handle the
volume of data produced. While many tools are available
for various aspects of refining NGS sequence data to ac-
tionable information, they usually require expert users to
put them together into an effective workflow. Processingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tools much more accessible to less technically savvy users,
but still require a great deal of bioinformatics expertise to
set up a fully-operational data analysis pipeline. Though
NGS has been incorporated into clinical testing at several
reference laboratories, purchasing the computing power
necessary to perform NGS testing is cost-prohibitive for the
vast majority of clinical diagnostics laboratories. The Galaxy
team addressed this limitation by providing CloudMan
[10]. CloudMan is available as an Amazon Web Services
(AWS) public Amazon Machine Image (AMI). CloudMan
is set up such that anyone with an AWS account can log
into Amazon’s infrastructure and start any size compute
cluster they need for their data at a relatively low per hour
rate. Building onto the initial CloudMan release, several
other tools such as Cloud BioLinux [11], BioCloudCentral
[12] and CloVR [13] have been created to improve various
operational aspects and to address specific use cases not
originally handled by CloudMan. However, none of these
solutions met the needs of our clinical application since the
storage needs for these solutions did not give us the flexibil-
ity we needed to control storage costs and obtain a pipeline
that was cost-effective on a per-sample basis. CloudMan for
instance requires the usage of EBS disk while running ana-
lyses, which can be substantial. Our solution does not re-
quire the usage of EBS disk to run a sample - it only uses
the transient storage associated with the compute instances
that the pipelines are running. In addition to saving money -
this makes it easier to predict costs and simplifies the
startup and shutdown of these instances.
Our software makes it possible to control storage costs
providing a solution that is cost-effective for clinical appli-
cations. In addition, another advantage of our software is
that it was implemented using libcloud and hence is amen-
able to any other cloud infrastructure libcloud can target
such as VMware vCloud (http://vcloud.vmware.com/) or
OpenStack (http://www.openstack.org/).
As required by the Clinical Laboratory Improvement
Amendment of 1988 (CLIA) [14], transitioning these tech-
nologies from research to clinical applications requires de-
velopment of detailed standard operating procedures and
validation of these tools to demonstrate precision and re-
producibility in identifying the pathogenic genetic variants
[15]. We describe our approach to clinical validation and
implementation of a bioinformatics processing pipeline in
a molecular diagnostics laboratory using cloud computing
infrastructure to help manage per-sample analytical costs.
Implementation
One of the key considerations of this bioinformatics
pipeline beyond the obvious concerns of security and
accuracy was its ease of use for physicians, rather than
IT professionals. Galaxy is a tool dedicated to making
command line tools more accessible via a commonweb interface. Any command line tool can be readily
wrapped and displayed in Galaxy. Similarly, these tools
can be linked together in workflows that will reproduce
an analysis on other inputs.
The Cloud Variant Calling system allows a user to start
a preconfigured Galaxy server as a virtual machine on
AWS. The preconfigured Galaxy server is created by
including a subset of tools from the main Galaxy server
together with a few tools developed at the University of
Minnesota. These additional tools, not in the main
Galaxy distribution, are under “MSI” or “Masonic Cancer
Center” on the tools pane. The user specifies sequence
data to be uploaded to the machine as part of the config-
uration of the virtual machine. Once complete, the user is
able to run prebuilt workflows to process the data and
produce a set of variations from the hg19 reference gen-
ome present in the selected genes in the sample.
To use the software package, the user executes a se-
cure shell (SSH) script with references to a sample sheet
describing the dataset and the raw, unprocessed FASTQ
files produced by the sequencer. The shell script launches a
Python process that uses Python virtualenv to request sev-
eral Python libraries, the most noteworthy of these librar-
ies being libcloud and the Minnesota Supercomputing
Institute’s (MSI) Galaxy Virtual Machine (VM) Launcher.
Galaxy VM Launcher uses libcloud and the AWS creden-
tials provided to create a new VM from the selected, pre-
configured Galaxy AMI. Galaxy VM Launcher connects
to the VM via SSH for further runtime configuration and
to upload the sample files.
Since the secure copy (SCP) connection between the
hosts broke at a surprisingly high frequency during ini-
tial testing, we implemented a system of dividing the
file into small pieces and retrying whenever there is a
failure. The size of file chunks is configurable, but de-
faults to 10 MB. Additionally, file chunks may be com-
pressed, but depending on connection speed and disk
speed, transfer without compression may be faster than
compressing before transferring.
The Cloud Variant Calling AMI contains a static version
of Galaxy with open source tools linked in pre-configured
workflows. Each VM generated from the AMI will be
identical with the exception of the data uploaded for
analysis. The tools and workflows included in the pub-
lished version require an instance type of ‘m2.xlarge’
(http://aws.amazon.com/ec2/instance-types/) due to rela-
tively high memory requirements for the GATK Unified
Genotyper. By running one VM per sample, several samples
can be analyzed in parallel without impacting each other in
any way. The only limit to the number of parallel analyses
is the number of VMs allowed on the AWS account. By de-
fault, this is 20, but this can be expanded upon request. All
communication between systems is done via SSH. Every
AWS account has an SSH certificate that is used by the
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e-mails, the server side user must have an SSH certificate
that allows access to the server machine.
Results
From the user perspective
The Cloud Variant Calling software package, from an
end-user perspective, consisted of a command line tool
that launches a customized virtual machine with Galaxy
running and their data loaded for analysis. The user(s)
executed workflows to perform the analysis and down-
loaded the resulting outputs for manual review of the
Variant Call Formatted (VCF) variants, along with the
supporting alignments, which were inspected using the
Integrative genome viewer (IGV) [16,17]. In our cus-
tomized version, the workflow also created backup
copies of the relevant inputs and outputs. A flowchart
summarizing the main steps of the pipeline is pre-
sented in Figure 1.
Launching a VM required two inputs: a metadata file
describing the sequence data being uploaded for analysisFigure 1 Flowchart for analysis pipeline. A metadata file
describing the sequence data being uploaded for analysis together
with the location of the files are passed as input to a shell script.
The shell script configures the VM on Amazons AWS and uploads
data to the VM. A Galaxy workflow is used for Phase 1 of the
analysis. QC results are examined to verify data meets quality
thresholds. A second Galaxy workflow is used for Phase 2 of the
analyses producing a VCF file containing variants.and the location of the files to upload (“Meta-data” file
and “Data location” in Figure 1). A project directory was
created to store the inputs, and if configured, download
the key outputs of each workflow. Once the VM was
configured and files were uploaded, the hostname was
created to capture the URL of the VM. The custom in-
stallation at MSI notified users via e-mail when the VM
was ready.
By default, files were made accessible to the user via a
shared data library called “Uploaded data”. The configur-
ation files made it possible to create a name history for a
specific user and link the uploaded data to this history.
Hence, the users had fewer steps to follow before launching
the workflow. Likewise, workflows could explicitly be linked
in the users tool menu, or accessed under the workflow
menu at the top of the Galaxy window (Figure 2).
The provided workflows were constructed to work in
two phases. The first phase (“Phase 1” in Figure 1) per-
formed several quality control steps and aligned the data
to a reduced human genome (to speed up computation
time and reduce analysis cost without affecting accuracy)
that matches the 568 gene panel used at the University
of Minnesota along with homologous regions that match
at least one of the 120 bp capture baits with a minimum
of 75% identity for at least 48 bp in length. Workflows
were available for samples sequenced on one, two or
three lanes of an Illumina Hi-seq 2000 to account for
variations in number of clinical samples being analyzed
on a particular sequencing run. In a majority of the runs,
we multiplexed samples across three lanes to reduce the
likelihood of needing to resequence in the event of a fail-
ure in one lane of a run. The second phase (“Phase 2” in
Figure 1) used the alignments from the first phase to
generate known variants from the reference genome and
reduced them to the specific panel requested by the
physician. Resulting variants (“Variants” in Figure 1)
were downloaded and reviewed by genetic counselors
and pathologists to generate patient reports. For a de-
tailed explanation and guide to using the workflows,
see Additional file 1.
Amazon Web Services (AWS) costs
Runtime costs at AWS for the current deployment aver-
aged around $30-$40 per sample analyzed. This cost in-
cluded all compute time from launch including uploading
20 GB of data per sample, running both workflows, down-
loading results and human response time to the completion
of each of these steps. Uploading data took approximately
two hours, the first workflow ten hours and the second
workflow an additional two hours. Due to the memory re-
quirements of the process, the hourly rate for a VM was
$0.45. We averaged the cost of using the pipeline for actual
clinical data sets over a period of three months. A total of
110 samples with fastq files ranging from 27 GB to 42 GB
Figure 2 The Galaxy analysis pipeline. The URL gives a link to a virtual machine on the amazon cloud that runs the analysis pipeline. Galaxy
interface is configured to make the CLIA certified workflows accessible as tools under the tools pane (left pane). The center pane shows results
for one of the QC analyses (coverage plot outlining percent of bases with different levels of coverage). The right pane is a history of all the tools
and the order in which they were executed by the pipeline together their results.
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cost for the three months was $34.60.
Clinical validation
To meet clinical validation standards, four samples were
analyzed in duplicate through the entire system includ-
ing the analysis pipeline in the cloud to ensure that the
identical variations in specific exons were detected in
the duplicate samples. The four duplicate pairs showed
100% concordance in the mutations that were identified
during these analyses. Furthermore, this pipeline is cur-
rently being used in the clinic and all identified pathogenic
variants were confirmed using Sanger sequencing further
validating the software [18]. By freezing the entire virtual
machine, from operating system through the Galaxy ser-
ver to the individual tool versions, we were able to ensure
consistent results across multiple analyses. Periodic reanaly-
sis of these samples were used for continued validation that
the system was working properly due to the elements at
both AWS and MSI, which may change outside the control
of this particular project.
Discussion
We demonstrate the clinical validation and feasibility of
implementing a cloud based bioinformatics pipeline for
analysis of NGS data for use in a clinical molecular diag-
nostics laboratory.The analysis workflow described in this manuscript
can be completely customized for analysis of any panel
of genes. The workflow described for analysis of the 568
genes can be expanded or use an entirely separate set of
exons by replacing the reduced genome, exon interval
file and exon with 30 bp flanks BED file in the launcher/
common_files directory. To create a customized reduced
genome use the “Create Reduced Genome” workflow
included on the Cloud Variant Calling VM. The con-
tents of the launcher/common_files are uploaded to
every VM during initialization and the files are selected
where appropriate when running the other workflows.
Several options exist with regards to how to develop a
customized Galaxy for deployment as an AMI. Workflows
can be created on an existing local version of Galaxy then
exported. The exported workflow can be included in the
AMI during the AMI creation step. Alternatively, a local
development Galaxy can be created using Galaxy VM
Launcher on Virtual Box or Open Stack VM environ-
ments, or a development Galaxy can be deployed directly
to AWS. In any of these three cases, the development VM
will have to run from a local copy of the Galaxy repository
to be deployed on the final AMI. Any changes made to
the running system simply need to be committed to the
repository before the AMI is built. During construction of
the workflow it is important to consider the tools to be
used. Open source tools that are already available for
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the starting point for the Cloud Variant Calling AMI.
Deploying a tool that exists in the Ubuntu ecosystem
can be as simple as adding the package name to a con-
figuration file. However, it is possible to script the in-
stallation of other tools during AMI creation via the
Galaxy VM Launcher.
When the workflow and associated tools are ready to
be packaged into an AMI, the packaging script, package.
sh, included with the downloaded software can be run to
build a clean VM to create the AMI. Once the VM is
running, the user can connect via SSH and run through
the three steps presented in the AWS documentation on
creating a custom AMI. The resulting AMI ID from the
final registration step will be copied into the Galaxy VM
Launcher configuration for use in the deployment.
Much of the cost so far has been due to human and
other errors that have led to re-analysis of several sam-
ples. The most common cause so far has been discrep-
ancies in the gene names produced from the ordering
form used by the sequencing center and the exon inter-
val files used to filter results. The discrepancies and user
input validation have been resolved and eliminated from
our SOP so that costs are expected to decline to the es-
timated compute time cost of approximately $10 per
sample. In addition to these, other factors that could be
addressed are increased automation and performance
enhancements, both in terms of compute time and
memory requirements. Automation via BioBlend [19]
and the Galaxy API could reduce or eliminate any time
accumulated due to human response time. Streamlin-
ing the published workflow would directly reduce the
amount of time required to process a sample. Finally,
the per hour rate for compute time could be lowered if
reductions in the memory requirement can be made.
The hourly rate is based on which EC2 instance type is
selected for the VM. Once changes to any aspect of the
system are ready to be deployed, the validation proced-
ure can be applied prior to deploying the changes.
Galaxy VM Launcher is now a part of CloudBioLinux
[11] and BioCloudCentral [12] and is no longer under
active development. All three projects have similar goals
and requirements. The best parts of each continue on as
part of the remaining two projects. Future versions of the
Cloud Variant Calling application will use CloudBioLinux
[11] and be available for use via BioCloudCentral [12].
From a security standpoint, the data is encrypted in
transit, but the temporary storage used at Amazon is
not currently encrypted. While there is no protected
health information (PHI) associated with the data we
use and the sequence data is not a complete genome,
setting up an encrypted file system on each VM’s in-
stance specific file system would provide end-to-end
encryption during the analysis process.Conclusions
Several efforts are ongoing involving the analysis of NGS
data in the cloud [10-12,19,20]. The successful implemen-
tation of cloud based bioinformatics analysis pipeline in a
clinical laboratory demonstrates feasibility of using cloud
based resources in clinical settings. With end-to-end en-
cryption and the requisite care for encryption keys and
PHI in combination with the ability to control the tools
used, cloud based computing can be safely and reasonably
used for appropriate clinical use. The effort that is cur-
rently needed is bioinformatics to determine the most
common clinical applications and provide standardized
workflows via this or similar methods. Commercial com-
panies could also leverage this method to provide low cost
analysis as an add-on to sequencing data for clinicians.
Availability and requirements
Project Name: Cloud Variant Calling
Project Home Page: https://bitbucket.org/riss/cloud-
variant-calling
Operating System: Linux (tested on CentOS)
Programming Language: Python
License: GNU GPL
Other requirements: Amazon Web Services account
Guide on using Galaxy workflow for variant detection:
Additional file 1
Additional file
Additional file 1: Galaxy workflow Guide for Variant detection.
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